Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Buzz on the Bullboards: The Summer’s Most Talked About Sectors

Stockhouse Editorial
7 Comments| July 1, 2021

{{labelSign}}  Favorites

The summer trading season is well underway as we celebrate a holiday here in Canada and this weekend in the US. Even on days that the markets were closed, the Bullboards on Stockhouse are wide open and busy with lively discussions on some of the biggest (and smallest) stocks that investors are tracking.

This week, we highlight how investors react when shares make big gains, whether they were part of a climbing pattern or a sudden and unexpected surge, Stockhouse users responded smartly: with equal parts hope and skepticism.

Take for example, clinical stage company Antibe Therapeutics Inc. (TSX-V:ATE, Forum), whose recent $100 million (USD) partnership with Nuance Pharma in China drew investor attention to its hydrogen sulfide platform. The company is out to develop safer medicines for pain and inflammation.

Medical diagnostic and device technology company Therma Bright Inc. (TSX-V: THRM, Forum) has secured DME Authority for Venowave, a lightweight Deep Vein Thrombosis (DVT) prophylaxis device. The multi-year agreement provides Therma Bright with a $10 million annual minimum purchase commitment.

The Venowave is a lightweight battery-operated medical compression device designed to manage, treat and alleviate the symptoms associated with poor circulation. When worn firmly on the calf, the Venowave produces a waveform motion forcing blood from the feet and legs back to the heart. This increase in blood flow draws oxygen to wound and ulcer sites prevent blood pooling and clotting, treats Lymphedema, and alleviates symptoms of Post Thrombotic Syndrome and other Chronic Venous Insufficiencies.

Venowave is also uniquely designed for the emerging “Hospital to Home” use market, in the front-line battle against blood clot prevention. It delivers a continuous peristaltic wave motion and directly engages the body's venous system to increase venous blood flow more naturally and accurately, aiding in the prevention of blood clot formation.

With approximately 50% of Deep Vein Thrombosis forming during the surgical procedure itself, and an alarming 75% of DVT's forming within 48 hours of the patient returning home after surgery, this technology is pioneering an alternative life-saving treatment for this condition.

Studies have shown there are many risk factors and causes associated with Deep Vein Thrombosis (DVT), including surgery, post-surgical recovery, obesity, smoking, prolonged sitting, pregnancy, hospitalization, cancer, leg injuries, fractures, and certain birth-control & hormone-replacement medications.

As of a May 12th report, the US Centers for Disease Control and Prevention had received reports of at least 28 fatalities resulting from a rare blood clotting syndrome identified among the 8.7 million coronavirus vaccine recipients from one manufacturer. Therma Bright has begun exploring new and innovative applications of its Venowave intellectual properties to expand into any potential modality that would assist in further alleviation of these rising blood clot concerns.

Commenting on his company’s new, exclusive US distributorship with DME Authority, Therma Bright’s Chief Executive Officer, Rob Fia explained that its proprietary DME-360 software service model, in combination with Venowave’s unique therapeutic proficiencies, offers US Hospitals and Physician Practices the first true standard-of-care transformation capability this therapy category will have experienced in the last 30-plus years.

“This patented, FDA approved Venowave DVT prophylaxis device administers our proprietary peristaltic action to work against the formation of blood clots by also offering the best comfort, mobility, and ease-of-use in this product category, while ensuring improved blood flow within the lower extremities. That's meaningful, because comfort and convenience are a must-have if we are to expect higher consistency with patient compliance of the preventative therapy Venowave delivers.”

What the "Buzz"

Our Bullboards have up to 2 Million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.

Get "Buzz on the Bullboards" delivered to your inbox every Thursday!

Buzz on the Bullboards | Sign Up Here

Consumer packaged goods cannabis company HEXO Corp. (TSX: HEXO, Forum) has finalized the purchase of its first US production facility through a wholly-owned US subsidiary.

The 4,645 sq. metre (50,000 sq. ft.) facility in Fort Collins, Colorado will provide US CPG companies and consumers access to the Powered by HEXO technology and products.

HEXO Corp CEO and co-founder Sebastien St-Louis noted that the Colorado facility will allow the company to successfully execute on our US strategy, which includes supplying high quality Powered by HEXO technology and leveraging the team’s intellectual property portfolio across the United States.

“The facility will also provide us with the necessary infrastructure to continue expanding our joint-venture with Molson Coors to create Truss CBD-infused beverages, while also creating the necessary capacity to support future, non-beverage CPG partnerships.”

The Colorado production facility, HEXO’s first in the US, is zoned to produce a full range of cannabis products and offers a variety of operational capabilities. The site is located along primary shipping routes and will be retrofitted to support Powered by HEXO initiatives across the country, in compliance with all applicable laws and regulations.

Powered by HEXO is the trusted solution for leading CPG companies to safely enter the cannabinoid market, combining HEXO's expertise in cannabis with CPG partners’ expertise in their industries to co-develop best-in-class cannabinoid-infused products.

They say no news is bad news and that appears to be true for Reconnaissance Energy Africa Ltd. (TSX-V: RECO, Forum) stock.

RECO shares have climbed since the company called out National Geographic for publishing an article that accused the company of ignoring community concerns operating in Namibia, as well as exploring in sensitive elephant habitat, disposing of wastewater unsafely, without permits, and ignored concerns about potential impact of oil drilling on water and wildlife.

Then RECO did damage control last week after Globe & Mail’s article on its dealings with Canada’s securities regulators on the basis of environmental malpractice.

Now the embattled company is battling allegations that its oil basins don’t even exist. Investigative financial research group, Viceroy Research launched a report accusing ReconAfrica of “drilling imaginary oil basins in a fragile ecosystem”. Though ReconAfrica denied the report’s findings and wrote it off as biased, Viceroy explained that the oil company has yet to provide further information on the in-progress completion of several wells, including depth, the age of the rock in which they claim shows, show depth, and wireline / petrophysical data from the wells. The report went on to conclude that the only reason this data has not been released it because the wells were failures.

As of this writing, ReconAfrica has yet to respond to the numerous investigations that have been piling over possible securities fraud committed by the company and its work in the opening of the newly discovered deep Kavango Sedimentary Basin, in the Kalahari Desert of northeastern Namibia and northwestern Botswana.

New Found Gold (TSX-V: NFG, Forum) announced assay results from four holes drilled at the Golden Joint zone, a brand new discovery located approximately 1 km north of the Keats Zone and approximately 850 metres south of the Lotto Zone. These holes were drilled as part of the Company's ongoing 200,000 metre diamond drill program at its 100%-owned Queensway Project, located on the Trans-Canada Highway 15 km west of Gander, Newfoundland.

(Chart via New Found Gold.)

The intercept of 430.2 g/t Au over 5.25 metres in hole NFGC-21-241 represents a grade x width value of 2,258 g/t Au x meters, the second highest value encountered to date on the Queensway project. Furthermore, over 700 grains of gold were observed in this 5.25m intercept, representing the most per meter seen to date anywhere at the Queensway Project. The new Golden Joint discovery occurs in two to three sub parallel vein systems.

Elsewhere in Newfoundland, Sokoman Minerals Corp. (TSX-V: SIC, Forum) has staked even more claims with Benton Resources (TSX-V: BEX, Forum) to explore for gold.

Together, they entered into an agreement to acquire the Larry’s Pond project which consists of two licenses totalling 30 claim units. Multiple quartz veins and silicified zones have been discovered and sampled, containing sulfides (chalcopyrite and galena), for which results are pending.

Each sector is experiencing the uncertainty ride differently, and we want to know where your money is at. With many of our top sectors and most-viewed companies changing regularly, it’s important to check in and see where small-cap investors are focusing their investments, so head over to the Stockhouse Homepage or click the image below to add your voice and let us know.

With COVID-19 restrictions easing and travellers feeling more breathing room, two travel-related stocks have been, for lack of a worse pun, gaining altitude.

Air Canada Inc. (TSX: AC, Forum) stock has climbed 50% in the past year. This week, the airline launched the trial of a new digital solution available through its mobile app for customers to securely scan, upload and verify their COVID-19 test results. This feature will help travellers conveniently validate compliance with government health travel requirements prior to arriving at the airport. Air Canada has developed its new solution with the support of Amadeus, one of the world's leading travel technology companies. Initially available beginning June 29 for flights from Frankfurt to Toronto and Montréal, the airline plans to roll-out the solution across its network later this summer pending results of the trial and introduce new capabilities so that customers can also pre-validate proofs of vaccination.

Bombardier Inc. (TSX: BBD, Forum) has risen 120% on the year. This week, BBD announced that two of its Global 7500 aircraft were handed over to two different Canadian customers, marking the first deliveries of the flagship business jet in Canada. Both aircraft will be managed and offered for charter by leading Canadian aircraft services provider, Chartright Air Group, and will be based at Toronto’s Pearson International Airport.

Xebec Adsorption Inc. (TSX-V: XBC, Forum) is a global provider of clean energy solutions for renewable and low carbon gases used in energy, mobility and industrial applications. Its subsidiary, HyGear, has commissioned a hydrogen generation system for Turkey's first lubricant recycling plant.

TAYRAŞ’ used lubricant recycling plant is the first of its kind in the country and will be key to reducing Turkey's emissions from API Group II base lubricating oils. Approximately 560 kg of hydrogen a day (205 tonnes a year) would be delivered under 125 bar over a 15-year gas-as-a-service contract.

The hydrogen will be used to hydro-treat the oils and remove sulphur, chlorine, nitrogen, phosphorous, silica and saturation of aromatics employing special catalysts.TAYRAŞ’ plant can process 60,000 tons of used lubricating oil per year, which will yield 45,000 tonnes of Group II base oil (N70, N100, N220). According to Kline & Co., approximately 50% of used motor oil is re-refined in Europe. This amount falls to between 10%-15% in North America. In Turkey, Petder estimates it to be as little as 7%.

Xebec Europe President Marinus van Driel, commented that this was a significantly large sized project for us and a unique one to be involved in within our reference installations.

“TAYRAŞ’ re-refinery shows the importance of securing local supply and reducing the carbon footprint of oils through recycling. Our on-site hydrogen offers the lowest cost and emissions option by cutting out the transportation and liquefaction steps from centralized hydrogen supply. In addition, we were able to showcase our expertise in compression by operating at an impressive 125 bar on a 24/7 basis. This level of operation will lend well to other applications such as hydrogen refueling stations where this pressure and reliability is also needed.”

Xebec is a global provider of clean energy solutions for renewable and low carbon gases used in energy, mobility, and industrial applications.

This week for our Investor Pulse Poll, we want to know you a little better. A number of new Bullboard users have popped up and we are curious to know how generally familiar you are with personal finance. Click the image below to cast your vote.

(Click image to vote.)

Looking at last week’s poll, it seems just over half of you intend to keep busy this summer, juggling fun in the sun while the bears and bulls run.

Buzz on the Bullboards will be back next week, but the discussions on the Stockhouse Bullboards are always ongoing. They give members and visitors a chance to celebrate, speculate, and when necessary, vent about the companies you care about the most. For previous editions of Buzz on the Bullboards: click here.

Get "Buzz on the Bullboards" delivered to your inbox every Thursday!

Buzz on the Bullboards | Sign Up Here

{{labelSign}}  Favorites


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.